Exploring new treatment options for lung cancer driven by RIT1 mutations
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer
This study is looking at how changes in a gene called RIT1 affect lung cancer, specifically a common type called lung adenocarcinoma, to find better treatments that could help patients whose cancer is influenced by these gene changes.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11059146 on NIH RePORTER |
What this research studies
This research investigates the role of RIT1 mutations in lung adenocarcinomas, which are a common type of lung cancer. The study aims to understand how these mutations contribute to cancer progression and resistance to existing therapies. By identifying the mechanisms through which RIT1 mutations operate, the research seeks to develop new treatment strategies that could be more effective for patients with RIT1-driven lung cancer. Patients may benefit from novel therapies that target the specific vulnerabilities associated with their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung adenocarcinoma who have RIT1 mutations.
Not a fit: Patients without RIT1 mutations or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with RIT1-driven lung cancer, improving treatment outcomes.
How similar studies have performed: Other research has shown promise in targeting specific mutations in cancer, suggesting that this approach could be effective for RIT1-driven lung cancer as well.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Berger, Alice — Fred Hutchinson Cancer Center
- Study coordinator: Berger, Alice
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.